A number of firms have modified their ratings and price targets on shares of BIOLINERX Ltd/S (NASDAQ: BLRX) recently:

  • 11/14/2018 – BIOLINERX Ltd/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
  • 11/9/2018 – BIOLINERX Ltd/S was given a new $3.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/9/2018 – BIOLINERX Ltd/S was given a new $4.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 11/8/2018 – BIOLINERX Ltd/S had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $2.00 price target on the stock. They wrote, “BioLineRx reported 3Q18 with a net loss of ($6.2M) and ended the quarter with $35M in cash on the balance sheet. We estimate a runway to late 2019.””
  • 11/7/2018 – BIOLINERX Ltd/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
  • 10/22/2018 – BIOLINERX Ltd/S was given a new $4.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/16/2018 – BIOLINERX Ltd/S was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 10/15/2018 – BIOLINERX Ltd/S was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
  • 10/4/2018 – BIOLINERX Ltd/S was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 10/3/2018 – BIOLINERX Ltd/S was given a new $4.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.

NASDAQ BLRX opened at $0.64 on Tuesday. BIOLINERX Ltd/S has a one year low of $0.63 and a one year high of $1.84. The stock has a market capitalization of $71.35 million, a PE ratio of -2.37 and a beta of 0.87.

BIOLINERX Ltd/S (NASDAQ:BLRX) last posted its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). Analysts anticipate that BIOLINERX Ltd/S will post -0.22 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd purchased a new stake in BIOLINERX Ltd/S (NASDAQ:BLRX) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned 1.27% of BIOLINERX Ltd/S as of its most recent filing with the SEC. Hedge funds and other institutional investors own 35.81% of the company’s stock.

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Featured Article: Index Funds

Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.